Insmed | INSM - Pre Tax Profit


Insmed reported $-11.37M in Pre-Tax Profit for its fiscal quarter ending in June of 2026.





Pre Tax Profit Change Date
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Cytokinetics USD -206.03M 23M Mar/2026
DBV Technologies USD -47.4M 14.24M Mar/2026
Gilead Sciences USD -7.53B 10.11B Jun/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -11.37M 150.72M Jun/2026
Novartis USD 3.84B 1.33B Mar/2026
Regeneron Pharmaceuticals USD 1.53B 696.6M Jun/2026
Sarepta Therapeutics USD -1.75M 344.92M Jun/2026
Ultragenyx Pharmaceutical USD -91M 93M Jun/2026
Vertex Pharmaceuticals USD 1.39B 138.9M Jun/2026